Search

Your search keyword '"Lahuerta J.-J."' showing total 187 results
Start Over Author "Lahuerta J.-J."
187 results on '"Lahuerta J.-J."'

1. The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression

Author

Medina-Herrera, A., Vazquez, I., Cuenca, I., Rosa-Rosa, J. M., Ariceta, B., Jimenez, C., Fernandez-Mercado, M., Larrayoz, M. J., Gutierrez, N. C., Fernandez-Guijarro, M., Gonzalez-Calle, V., Rodriguez-Otero, P., Oriol, A., Rosiñol, L., Alegre, A., Escalante, F., De La Rubia, J., Teruel, A. I., De Arriba, F., Hernandez, M. T., Lopez-Jimenez, J., Ocio, E. M., Puig, N., Paiva, B., Lahuerta, J. J., Bladé, J., San Miguel, J. F., Mateos, M. V., Martinez-Lopez, J., Calasanz, M. J., and Garcia-Sanz, R.

Published
2024
Full Text
View/download PDF

2. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study

Author

Kumar, S K, Dimopoulos, M A, Kastritis, E, Terpos, E, Nahi, H, Goldschmidt, H, Hillengass, J, Leleu, X, Beksac, M, Alsina, M, Oriol, A, Cavo, M, Ocio, E M, Mateos, M V, O'Donnell, E K, Vij, R, Lokhorst, H M, van de Donk, N W C J, Min, C, Mark, T, Turesson, I, Hansson, M, Ludwig, H, Jagannath, S, Delforge, M, Kyriakou, C, Hari, P, Mellqvist, U, Usmani, S Z, Dytfeld, D, Badros, A Z, Moreau, P, Kim, K, Otero, P R, Lee, J H, Shustik, C, Waller, D, Chng, W J, Ozaki, S, Lee, J-J, de la Rubia, J, Eom, H S, Rosinol, L, Lahuerta, J J, Sureda, A, Kim, J S, and Durie, B G M

Published
2017
Full Text
View/download PDF

4. Differentiation stage of myeloma plasma cells: biological and clinical significance

Author

Paiva, B, Puig, N, Cedena, M T, de Jong, B G, Ruiz, Y, Rapado, I, Martinez-Lopez, J, Cordon, L, Alignani, D, Delgado, J A, van Zelm, M C, Van Dongen, J J M, Pascual, M, Agirre, X, Prosper, F, Martín-Subero, J I, Vidriales, M-B, Gutierrez, N C, Hernandez, M T, Oriol, A, Echeveste, M A, Gonzalez, Y, Johnson, S K, Epstein, J, Barlogie, B, Morgan, G J, Orfao, A, Blade, J, Mateos, M V, Lahuerta, J J, and San-Miguel, J F

Published
2017
Full Text
View/download PDF

5. Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma

Author

Perez C., Botta C., Zabaleta A., Puig N., Cedena M. -T., Goicoechea I., Alameda D., Jose-Eneriz E. S., Merino J., Rodriguez-Otero P., Maia C., Alignani D., Maiso P., Manrique I., Lara-Astiaso D., Vilas-Zornoza A., Sarvide S., Riillo C., Rossi M., Rosinol L., Oriol A., Blanchard M. -J., Rios R., Sureda A., Martin J., Martinez R., Bargay J., de la Rubia J., Hernandez M. -T., Martinez-Lopez J., Orfao A., Agirre X., Prosper F., Mateos M. -V., Lahuerta J. -J., Blade J., San-Miguel J. F., Paiva B., Espinosa M. C., Zamudio J. L. G., Herranz E. R., Tamayo R. R., Sanchez J. M., Bernal L. P., Rodriguez A. P. G., Garcia M. E. G., Mayol A. S., Lleonart J. B., Suarez A., Garcia M. T. H., Gaisan C. M., Ruiz B. H., Montero F. C., de Miguel Llorente D., Ramos F. S., Garcia A. I., Manteca M. M., Martin J. M. H., Barrigon F. E., Frade J. G., de Coca A. G., Franco C. A., Gomez J. L., Perez E. C., Creixenti J. B., Balari A. M. S., Montes Y. G., Teigell L. E., Guinon A. G., Monreal E. A., Campos J. A. S., Tutusaus J. M. M., Rocafiguera A. O., Gorrochategui M. G., Mesa M. G., Silva C. C., Perez M. S. G., Loureiro A. D., Sanchez J. A. M., Irazu M. J. N., Parraga F. J. P., Palacios J. J. L., Barahona P. B., Rodriguez C. E., Rivas J. A. H., de Oteyza J. P., del Barrio R. I., de la Guia A. L., Amor A. A., Pareja E. P., Castello I. K., Rodriguez M. J. B., Martinez R. M., Grau R. R., Mesa E. G., Sainz E. R., de Arriba F., Jimenez J. M. M., Romera M., Cardoso F. P., Perez J. M. A., Pomposo M. P., Persona E. P., Casasus A. I. T., Garcia P. R., Ramos I. J., Lor M. B. V., Garcia P. L. F., Chamorro C. M., Perez C., Botta C., Zabaleta A., Puig N., Cedena M.-T., Goicoechea I., Alameda D., Jose-Eneriz E.S., Merino J., Rodriguez-Otero P., Maia C., Alignani D., Maiso P., Manrique I., Lara-Astiaso D., Vilas-Zornoza A., Sarvide S., Riillo C., Rossi M., Rosinol L., Oriol A., Blanchard M.-J., Rios R., Sureda A., Martin J., Martinez R., Bargay J., de la Rubia J., Hernandez M.-T., Martinez-Lopez J., Orfao A., Agirre X., Prosper F., Mateos M.-V., Lahuerta J.-J., Blade J., San-Miguel J.F., Paiva B., Espinosa M.C., Zamudio J.L.G., Herranz E.R., Tamayo R.R., Sanchez J.M., Bernal L.P., Rodriguez A.P.G., Garcia M.E.G., Mayol A.S., Lleonart J.B., Suarez A., Garcia M.T.H., Gaisan C.M., Ruiz B.H., Montero F.C., de Miguel Llorente D., Ramos F.S., Garcia A.I., Manteca M.M., Martin J.M.H., Barrigon F.E., Frade J.G., de Coca A.G., Franco C.A., Gomez J.L., Perez E.C., Creixenti J.B., Balari A.M.S., Montes Y.G., Teigell L.E., Guinon A.G., Monreal E.A., Campos J.A.S., Tutusaus J.M.M., Rocafiguera A.O., Gorrochategui M.G., Mesa M.G., Silva C.C., Perez M.S.G., Loureiro A.D., Sanchez J.A.M., Irazu M.J.N., Parraga F.J.P., Palacios J.J.L., Barahona P.B., Rodriguez C.E., Rivas J.A.H., de Oteyza J.P., del Barrio R.I., de la Guia A.L., Amor A.A., Pareja E.P., Castello I.K., Rodriguez M.J.B., Martinez R.M., Grau R.R., Mesa E.G., Sainz E.R., de Arriba F., Jimenez J.M.M., Romera M., Cardoso F.P., Perez J.M.A., Pomposo M.P., Persona E.P., Casasus A.I.T., Garcia P.R., Ramos I.J., Lor M.B.V., Garcia P.L.F., and Chamorro C.M.

Subjects
Male, Transcription, Genetic, Neutrophils, T-Lymphocytes, Immunology, CD33, Biology, CD16, Biochemistry, Follow-Up Studie, Flow cytometry, Antigens, CD, medicine, Humans, Cytotoxic T cell, Lymphocyte Count, Tumor microenvironment, medicine.diagnostic_test, Myeloid-Derived Suppressor Cells, Cell Biology, Hematology, Middle Aged, Cell sorting, Neoplasm Proteins, medicine.anatomical_structure, T-Lymphocyte, Cancer research, Myeloid-derived Suppressor Cell, Female, Bone marrow, Multiple Myeloma, Human, Follow-Up Studies
Abstract

Granulocytic myeloid-derived suppressor cells (G-MDSCs) promote tumor growth and immunosuppression in multiple myeloma (MM). However, their phenotype is not well established for accurate monitoring or clinical translation. We aimed to provide the phenotypic profile of G-MDSCs based on their prognostic significance in MM, immunosuppressive potential, and molecular program. The preestablished phenotype of G-MDSCs was evaluated in bone marrow samples from controls and MM patients using multidimensional flow cytometry; surprisingly, we found that CD11b+CD14−CD15+CD33+HLADR− cells overlapped with common eosinophils and neutrophils, which were not expanded in MM patients. Therefore, we relied on automated clustering to unbiasedly identify all granulocytic subsets in the tumor microenvironment: basophils, eosinophils, and immature, intermediate, and mature neutrophils. In a series of 267 newly diagnosed MM patients (GEM2012MENOS65 trial), only the frequency of mature neutrophils at diagnosis was significantly associated with patient outcome, and a high mature neutrophil/T-cell ratio resulted in inferior progression-free survival (P < .001). Upon fluorescence-activated cell sorting of each neutrophil subset, T-cell proliferation decreased in the presence of mature neutrophils (0.5-fold; P = .016), and the cytotoxic potential of T cells engaged by a BCMA×CD3-bispecific antibody increased notably with the depletion of mature neutrophils (fourfold; P = .0007). Most interestingly, RNA sequencing of the 3 subsets revealed that G-MDSC–related genes were specifically upregulated in mature neutrophils from MM patients vs controls because of differential chromatin accessibility. Taken together, our results establish a correlation between the clinical significance, immunosuppressive potential, and transcriptional network of well-defined neutrophil subsets, providing for the first time a set of optimal markers (CD11b/CD13/CD16) for accurate monitoring of G-MDSCs in MM.

Published
2020

7. Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma

Author

Flores-Montero, J, Sanoja-Flores, L, Paiva, B, Puig, N, García-Sánchez, O, Böttcher, S, van der Velden, V HJ, Pérez-Morán, J-J, Vidriales, M-B, García-Sanz, R, Jimenez, C, González, M, Martínez-López, J, Corral-Mateos, A, Grigore, G-E, Fluxá, R, Pontes, R, Caetano, J, Sedek, L, del Cañizo, M-C, Bladé, J, Lahuerta, J-J, Aguilar, C, Bárez, A, García-Mateo, A, Labrador, J, Leoz, P, Aguilera-Sanz, C, San-Miguel, J, Mateos, M-V, Durie, B, van Dongen, J JM, and Orfao, A

Published
2017
Full Text
View/download PDF

8. Second primary malignancies in multiple myeloma: an overview and IMWG consensus

Author

Musto, P., Anderson, K. C., Attal, M., Richardson, P. G., Badros, A., Hou, J., Comenzo, R., Du, J., Durie, B. G. M., San Miguel, J., Einsele, H., Chen, W. M., Garderet, L., Pietrantuono, G., Hillengass, J., Kyle, R. A., Moreau, P., Lahuerta, J. J., Landgren, O., Ludwig, H., Larocca, A., Mahindra, A., Cavo, M., Mazumder, A., McCarthy, P. L., Nouel, A., Rajkumar, S. V., Reiman, A., Serra, E. R., Sezer, O., Terpos, E., Turesson, I., Usmani, S., Weiss, B. M., and Palumbo, A.

Published
2017
Full Text
View/download PDF

9. Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential

Author

Paíno, T, Paiva, B, Sayagués, J M, Mota, I, Carvalheiro, T, Corchete, L A, Aires-Mejía, I, Pérez, J J, Sanchez, M L, Barcena, P, Ocio, E M, San-Segundo, L, Sarasquete, M E, García-Sanz, R, Vidriales, M-B, Oriol, A, Hernández, M-T, Echeveste, M-A, Paiva, A, Blade, J, Lahuerta, J-J, Orfao, A, Mateos, M-V, Gutiérrez, N C, and San-Miguel, J F

Published
2015
Full Text
View/download PDF

10. Prognostic value of serum paraprotein response kinetics in patients with newly diagnosed multiple myeloma

Author

Tamariz-Amador, Luis-Esteban, Rodríguez-Otero, Paula, Jiménez-Ubieto, Ana, Rosiñol, Laura, Oriol, Albert, Ríos-Tamayo, Rafael, Sureda, Anna, Blanchard, María Jesús, Hernández, Miguel Teodoro, Cabañas Perianes, Valentín, Jarque, Isidro, Bargay, Joan, Gironella, Mercedes, De Arriba, Felipe, Palomera, Luís, González-Montes, Yolanda, Martí, José M., Krsnik, Isabel, Arguiñano, José María, González, Maríua Ester, Casado Montero, Luis Felipe, González-Rodriguez, Ana Pilar, López-Anglada, Lucía, Puig, Noemí, Cedena, María Teresa, Paiva, Bruno, Mateos, M. V, San-Miguel, J, Lahuerta, J. J, Bladé Creixenti, Juan, Trocóniz, Iñaki F., Universitat Autònoma de Barcelona, Institut Català de la Salut, [Tamariz-Amador LE, Rodríguez-Otero P] Clínica Universidad de Navarra, CCUN, Centro de Investigación Médica Aplicada (CIMA), IDISNA, CIBERONC, Pamplona, Spain. [Jiménez-Ubieto A] Hospital 12 de Octubre, Madrid, Spain. [Rosiñol L] Hospital Clínic de Barcelona, IDIBAPS, Barcelona, Spain. [Oriol A] Institut Català d'Oncologia i Institut Josep Carreras, Badalona, Spain. [Ríos R] Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain. [Gironella M] Vall d’Hebron Hospital Universitari, Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus

Subjects
Mieloma múltiple - Tractament, Cancer Research, Neoplasm, Residual, Pronòstic mèdic, Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], Time to best response, Other subheadings::Other subheadings::/drug therapy [Other subheadings], Quimioteràpia combinada, Early treatment failure, Prognostic marker, Multiple myeloma, Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Antineoplastic Combined Chemotherapy Protocols, neoplasias::neoplasias por tipo histológico::neoplasias de células plasmáticas::mieloma múltiple [ENFERMEDADES], Humans, Depht of response, Mieloma múltiple - Prognosi, Mieloma múltiple, terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Neoplasms::Neoplasms by Histologic Type::Neoplasms, Plasma Cell::Multiple Myeloma [DISEASES], Hematology, Prognosis, Treatment Outcome, Oncology, Multiple Myeloma, Paraproteins, Newly diagnosed myeloma
Abstract

Response kinetics is not well-established as a prognostic marker in multiple myeloma (MM). We developed a mathematical model to assess the prognostic value of serum monoclonal component (MC) response kinetics during 6 induction cycles in 373 newly diagnosed MM patients. The model calculated a resistance parameter that reflects the stagnation in the response after an initial descent, dividing the patients into two kinetics categories with significantly different progression-free survival (PFS). Introduction: Response kinetics is a well-established prognostic marker in acute lymphoblastic leukemia. The situation is not clear in multiple myeloma (MM) despite having a biomarker for response monitoring (monoclonal component [MC]). Materials and Methods: We developed a mathematical model to assess the prognostic value of serum MC response kinetics during 6 induction cycles, in 373 NDMM transplanted patients treated in the GEM2012Menos65 clinical trial. The model calculated a resistance parameter that reflects the stagnation in the response after an initial descent. Results: Two patient subgroups were defined based on low and high resistance, that respectively captured sensitive and refractory kinetics, with progression-free survival (PFS) at 5 years of 72% and 59% (HR 0.64, 95% CI 0.44-0.93; P =.02). Resistance significantly correlated with depth of response measured after consolidation (80.9% CR and 68.4% minimal residual disease negativity in patients with sensitive vs. 31% and 20% in those with refractory kinetics). Furthermore, it modulated the impact of reaching CR after consolidation; thus, within CR patients those with refractory kinetics had significantly shorter PFS than those with sensitive kinetics (median 54 months vs. NR; P =.02). Minimal residual disease negativity abrogated this effect. Our study also questions the benefit of rapid responders compared to late responders (5-year PFS 59.7% vs. 76.5%, respectively [P

Published
2022

11. New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)

Author

Ocio, E M, Richardson, P G, Rajkumar, S V, Palumbo, A, Mateos, M V, Orlowski, R, Kumar, S, Usmani, S, Roodman, D, Niesvizky, R, Einsele, H, Anderson, K C, Dimopoulos, M A, Avet-Loiseau, H, Mellqvist, U-H, Turesson, I, Merlini, G, Schots, R, McCarthy, P, Bergsagel, L, Chim, C S, Lahuerta, J J, Shah, J, Reiman, A, Mikhael, J, Zweegman, S, Lonial, S, Comenzo, R, Chng, W J, Moreau, P, Sonneveld, P, Ludwig, H, Durie, B G M, and Miguel, J F S

Published
2014
Full Text
View/download PDF

12. Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry

Author

Puig, N, Sarasquete, M E, Balanzategui, A, Martínez, J, Paiva, B, García, H, Fumero, S, Jiménez, C, Alcoceba, M, Chillón, M C, Sebastián, E, Marín, L, Montalbán, M A, Mateos, M V, Oriol, A, Palomera, L, de la Rubia, J, Vidriales, M B, Bladé, J, Lahuerta, J J, González, M, Miguel, J F S, and García-Sanz, R

Published
2014
Full Text
View/download PDF

13. A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control

Author

Paiva, B, Vídriales, M-B, Rosiñol, L, Martínez-López, J, Mateos, M-V, Ocio, E M, Montalbán, M-Á, Cordón, L, Gutiérrez, N C, Corchete, L, Oriol, A, Terol, M-J, Echeveste, M-A, De Paz, R, De Arriba, F, Palomera, L, de la Rubia, J, Díaz-Mediavilla, J, Granell, M, Gorosquieta, A, Alegre, A, Orfao, A, Lahuerta, J-J, Bladé, J, and Miguel, J F San

Published
2013
Full Text
View/download PDF

14. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group

Author

Fernández de Larrea, C, Kyle, R A, Durie, B G M, Ludwig, H, Usmani, S, Vesole, D H, Hajek, R, San Miguel, J F, Sezer, O, Sonneveld, P, Kumar, S K, Mahindra, A, Comenzo, R, Palumbo, A, Mazumber, A, Anderson, K C, Richardson, P G, Badros, A Z, Caers, J, Cavo, M, LeLeu, X, Dimopoulos, M A, Chim, C S, Schots, R, Noeul, A, Fantl, D, Mellqvist, U-H, Landgren, O, Chanan-Khan, A, Moreau, P, Fonseca, R, Merlini, G, Lahuerta, J J, Bladé, J, Orlowski, R Z, and Shah, J J

Published
2013
Full Text
View/download PDF

15. Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients

Author

Paiva, B, Gutiérrez, N-C, Chen, X, Vídriales, M-B, Montalbán, M-Á, Rosiñol, L, Oriol, A, Martínez-López, J, Mateos, M-V, López-Corral, L, Díaz-Rodríguez, E, Pérez, J-J, Fernández-Redondo, E, de Arriba, F, Palomera, L, Bengoechea, E, Terol, M-J, de Paz, R, Martin, A, Hernández, J, Orfao, A, Lahuerta, J-J, Bladé, J, Pandiella, A, and Miguel, J-F San

Published
2012
Full Text
View/download PDF

16. Management of treatment-emergent peripheral neuropathy in multiple myeloma

Author

Richardson, P G, Delforge, M, Beksac, M, Wen, P, Jongen, J L, Sezer, O, Terpos, E, Munshi, N, Palumbo, A, Rajkumar, S V, Harousseau, J L, Moreau, P, Avet-Loiseau, H, Lee, J H, Cavo, M, Merlini, G, Voorhees, P, Chng, W J, Mazumder, A, Usmani, S, Einsele, H, Comenzo, R, Orlowski, R, Vesole, D, Lahuerta, J J, Niesvizky, R, Siegel, D, Mateos, M-V, Dimopoulos, M, Lonial, S, Jagannath, S, Bladé, J, Miguel, J San, Morgan, G, Anderson, K C, Durie, B G M, and Sonneveld, P

Published
2012
Full Text
View/download PDF

17. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

Author

Kumar, S K, Lee, J H, Lahuerta, J J, Morgan, G, Richardson, P G, Crowley, J, Haessler, J, Feather, J, Hoering, A, Moreau, P, LeLeu, X, Hulin, C, Klein, S K, Sonneveld, P, Siegel, D, Bladé, J, Goldschmidt, H, Jagannath, S, Miguel, J S, Orlowski, R, Palumbo, A, Sezer, O, Rajkumar, S V, and Durie, B G M

Published
2012
Full Text
View/download PDF

18. Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myeloma

Author

Paiva, B, Pérez-Andrés, M, Vídriales, M-B, Almeida, J, de las Heras, N, Mateos, M-V, López-Corral, L, Gutiérrez, N C, Blanco, J, Oriol, A, Hernández, M T, de Arriba, F, de Coca, A G, Terol, M-J, de la Rubia, J, González, Y, Martín, A, Sureda, A, Schmidt-Hieber, M, Schmitz, A, Johnsen, H E, Lahuerta, J-J, Bladé, J, San-Miguel, J F, and Orfao, A

Published
2011
Full Text
View/download PDF

19. Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis

Author

Gutiérrez, N C, Castellanos, M V, Martín, M L, Mateos, M V, Hernández, J M, Fernández, M, Carrera, D, Rosiñol, L, Ribera, J M, Ojanguren, J M, Palomera, L, Gardella, S, Escoda, L, Hernández-Boluda, J C, Bello, J L, de la Rubia, J, Lahuerta, J J, and San Miguel, J F

Published
2007
Full Text
View/download PDF

20. Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality

Author

Martínez-López, Joaquín, Mateos, M. V., Encinas, C., Sureda, A., Hernández-Rivas, J. Á., Lopez de la Guía, A., Conde, D., Krsnik, I., Prieto, E., Riaza Grau, R., Gironella, Mercedes, Blanchard, M. J., Caminos, N., Fernández de Larrea, C., Senin, Alicia., Escalante, F., de la Puerta, J. E., Giménez, E., Martínez-Barranco, P., Mateos, J. J., Casado Montero, Luis Felipe, Bladé, J., Lahuerta, J. J., De la Cruz, Javier, San-Miguel, J., Universitat Autònoma de Barcelona, Martínez-López, Joaquín, Mateos, Maria Victoria, Lahuerta, Juan José, San-Miguel, Jesús, Martínez-López, Joaquín [0000-0001-7908-0063], Mateos, Maria Victoria [0000-0003-2390-1218], Lahuerta, Juan José [0000-0002-3393-9570], San-Miguel, Jesús [0000-0002-9183-4857], Institut Català de la Salut, and Vall d'Hebron Barcelona Hospital Campus

Subjects
Male, Multivariate analysis, Epidemiology, Myeloma, Disease, Comorbidity, técnicas de investigación::métodos epidemiológicos::recopilación de datos::estadísticas vitales::mortalidad [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Kidney, COVID-19 (Malaltia), Severity of Illness Index, 0302 clinical medicine, Multiple myeloma, virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES], Neoplasms::Neoplasms by Histologic Type::Neoplasms, Plasma Cell::Multiple Myeloma [DISEASES], Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES], Hematology, Middle Aged, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Prognosis, Hospitalization, Oncology, 030220 oncology & carcinogenesis, Cohort, Investigative Techniques::Epidemiologic Methods::Data Collection::Vital Statistics::Mortality [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Infectious diseases, Female, Drug therapy, Coronavirus Infections, Multiple Myeloma, medicine.medical_specialty, Pronòstic mèdic, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Pneumonia, Viral, lcsh:RC254-282, Article, 03 medical and health sciences, Betacoronavirus, Pharmacotherapy, Internal medicine, Severity of illness, Mortalitat, medicine, neoplasias::neoplasias por tipo histológico::neoplasias de células plasmáticas::mieloma múltiple [ENFERMEDADES], Humans, Pandemics, Aged, Inpatients, Inpatient mortality, business.industry, SARS-CoV-2, Mieloma múltiple, COVID-19, medicine.disease, Pneumonia, Increased risk, business, 030215 immunology
Abstract

There is limited information on the characteristics, prognostic factors, and outcomes of patients with multiple myeloma (MM) hospitalized with COVID-19. This retrospective case series investigated 167 patients reported from 73 hospitals within the Spanish Myeloma Collaborative Group network in March and April, 2020. Outcomes were compared with 167 randomly selected, contemporary, age-/sex-matched noncancer patients with COVID-19 admitted at six participating hospitals. Among MM and noncancer patients, median age was 71 years, and 57% of patients were male; 75 and 77% of patients, respectively, had at least one comorbidity. COVID-19 clinical severity was moderate–severe in 77 and 89% of patients and critical in 8 and 4%, respectively. Supplemental oxygen was required by 47 and 55% of MM and noncancer patients, respectively, and 21%/9% vs 8%/6% required noninvasive/invasive ventilation. Inpatient mortality was 34 and 23% in MM and noncancer patients, respectively. Among MM patients, inpatient mortality was 41% in males, 42% in patients aged >65 years, 49% in patients with active/progressive MM at hospitalization, and 59% in patients with comorbid renal disease at hospitalization, which were independent prognostic factors on adjusted multivariate analysis. This case series demonstrates the increased risk and identifies predictors of inpatient mortality among MM patients hospitalized with COVID-19.

Published
2020

21. Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma

Author

Medina, Alejandro, Puig, N., Flores-Montero, Juan, Jimenez, C., Sarasquete, M. E., García-Álvarez, M., Prieto-Conde, I., Chillon, C., Alcoceba, Miguel, Gutierrez, N. C., Oriol, Albert, Rosinol, L., Bladé Creixenti, Juan, Gironella, Mercedes, Hernandez, M. T., Gonzalez-Calle, V., Cedena, María Teresa, Paiva, Bruno, San-Miguel, J., Lahuerta, J. J., Mateos, M. V., Martínez-López, Joaquín, Orfao, Alberto, Gonzalez, M, García-Sanz, Ramón, Universitat Autònoma de Barcelona, Institut Català de la Salut, [Medina A, Puig N, Jimenez C, Sarasquete ME, Garcia-Alvarez M] Departamento de Hematología, Hospital Universitario de Salamanca (HUSA/ IBSAL), CIBERONC, CIC-IBMCC (USAL-CSIC), Salamanca, Spain. [Flores-Montero J] Centro de Investigación del Cáncer-IBMCC (USAL-CSIC), CIBERONC, Salamanca, Spain. [Gironella M] Vall d’Hebron Hospital Universitari, Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus

Subjects
Adult, Male, Oncology, medicine.medical_specialty, Nucleòtids - Anàlisi, Neoplasm, Residual, Myeloma, lcsh:RC254-282, Disease-Free Survival, Article, DNA sequencing, EuroFlow, Internal medicine, medicine, neoplasias::neoplasias por tipo histológico::neoplasias de células plasmáticas::mieloma múltiple [ENFERMEDADES], Humans, In patient, Survival rate, Multiple myeloma, Proportional hazards model, business.industry, Mieloma múltiple, Neoplasms::Neoplasms by Histologic Type::Neoplasms, Plasma Cell::Multiple Myeloma [DISEASES], High-Throughput Nucleotide Sequencing, Hematology, Middle Aged, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Flow Cytometry, medicine.disease, Minimal residual disease, técnicas de investigación::técnicas genéticas::análisis de secuencias [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Survival Rate, Transplantation, Investigative Techniques::Genetic Techniques::Sequence Analysis [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Risk factors, Female, Multiple Myeloma, business, Follow-Up Studies
Abstract

© The Author(s) 2020., Detecting persistent minimal residual disease (MRD) allows the identification of patients with an increased risk of relapse and death. In this study, we have evaluated MRD 3 months after transplantation in 106 myeloma patients using a commercial next-generation sequencing (NGS) strategy (LymphoTrack®), and compared the results with nextgeneration flow (NGF, EuroFlow). The use of different marrow pulls and the need of concentrating samples for NGS biased the applicability for MRD evaluation and favored NGF. Despite that, correlation between NGS and NGF was high (R2 = 0.905). The 3-year progression-free survival (PFS) rates by NGS and NGF were longer for undetectable vs. positive patients (NGS: 88.7% vs. 56.6%; NGF: 91.4% vs. 50%; p < 0.001 for both comparisons), which resulted in a 3-year overall survival (OS) advantage (NGS: 96.2% vs. 77.3%; NGF: 96.6% vs. 74.9%, p < 0.01 for both comparisons). In the Cox regression model, NGS and NGF negativity had similar results but favoring the latter in PFS (HR: 0.20, 95% CI: 0.09–0.45, p < 0.001) and OS (HR: 0.21, 95% CI: 0.06–0.75, p = 0.02). All these results reinforce the role of MRD detection by different strategies in patient prognosis and highlight the use of MRD as an endpoint for multiple myeloma treatment.

Published
2020

22. Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients

Author

Medina, Alejandro, Jiménez, C., Sarasquete, M. E., González, M., Chillón, M. Carmen, Balanzategui, A., Prieto-Conde, I., García-Álvarez, M., Puig, N., González-Calle, Verónica, Alcoceba, Miguel, Cuenca, I., Barrio, S., Escalante, F., Gutiérrez, N. C., Gironella, Mercedes, Hernández, M. T., Sureda, A., Oriol, Albert, Bladé Creixenti, Juan, Lahuerta, J. J., San Miguel, J. F., Mateos, M. V., Martínez-López, J., Calasanz, M.J, García-Sanz, Ramón, Universitat Autònoma de Barcelona, Instituto de Salud Carlos III, Ministerio de Economía y Competitividad (España), Fundación CRIS contra el Cáncer, Fundacion de la Sociedad Española de Hematología y Hemoterapia, Universidad de Salamanca, European Commission, Institut Català de la Salut, [Medina A, Jiménez C, Sarasquete ME, González M, Chillón MC, Balanzategui A] Hospital Universitario de Salamanca (HUSAL), IBSAL, IBMCC (USAL-CSIC), CIBERONC, Salamanca, Spain. [Gironella M] Vall d’Hebron Hospital Universitari, Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus

Subjects
Oncology, Male, Immunoglobulin Variable Region, Myeloma, Disease, fenómenos genéticos::regulación de la expresión génica::regulación de la expresión génica neoplásica [FENÓMENOS Y PROCESOS], Pathogenesis, Multiple myeloma, Genetics research, Aged, 80 and over, Gene Rearrangement, Univariate analysis, biology, Neoplasms::Neoplasms by Histologic Type::Neoplasms, Plasma Cell::Multiple Myeloma [DISEASES], Hematology, Middle Aged, Prognosis, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Gene Expression Regulation, Neoplastic, Multigene Family, Female, Antibody, Immunoglobulin Heavy Chains, Multiple Myeloma, Adult, medicine.medical_specialty, Cèl·lules B, Genetic Phenomena::Gene Expression Regulation::Gene Expression Regulation, Neoplastic [PHENOMENA AND PROCESSES], Somatic hypermutation, lcsh:RC254-282, Article, Internal medicine, Regulació genètica, medicine, Biomarkers, Tumor, Humans, neoplasias::neoplasias por tipo histológico::neoplasias de células plasmáticas::mieloma múltiple [ENFERMEDADES], Gene, Aged, B cells, business.industry, Gene Expression Profiling, Mieloma múltiple, medicine.disease, Transplantation, biology.protein, business, Follow-Up Studies
Abstract

Multiple myeloma is a heterogeneous disease whose pathogenesis has not been completely elucidated. Although B-cell receptors play a crucial role in myeloma pathogenesis, the impact of clonal immunoglobulin heavy-chain features in the outcome has not been extensively explored. Here we present the characterization of complete heavy-chain gene rearrangements in 413 myeloma patients treated in Spanish trials, including 113 patients characterized by next-generation sequencing. Compared to the normal B-cell repertoire, gene selection was biased in myeloma, with significant overrepresentation of IGHV3, IGHD2 and IGHD3, as well as IGHJ4 gene groups. Hypermutation was high in our patients (median: 8.8%). Interestingly, regarding patients who are not candidates for transplantation, a high hypermutation rate (≥7%) and the use of IGHD2 and IGHD3 groups were associated with improved prognostic features and longer survival rates in the univariate analyses. Multivariate analysis revealed prolonged progression-free survival rates for patients using IGHD2/IGHD3 groups (HR: 0.552, 95% CI: 0.361−0.845, p = 0.006), as well as prolonged overall survival rates for patients with hypermutation ≥7% (HR: 0.291, 95% CI: 0.137−0.618, p = 0.001). Our results provide new insights into the molecular characterization of multiple myeloma, highlighting the need to evaluate some of these clonal rearrangement characteristics as new potential prognostic markers., This work was partially supported by the Instituto de Salud Carlos III (ISCIII), Spanish Ministry of Economy and Competitiveness PI15/01956, CIBERONC-CB16/12/00233, and “Una manera de hacer Europa” (Innocampus; CEI-2010-1-0010)”. M.G.-A., I.P.-C., and C.J. are supported by the Fundación Española de Hematología y Hemoterapia (FEHH, co-funded by Fundación Cris in the latter case), A.M. by the European Social Fund and the Spanish Education Council through the University of Salamanca, and M.E.S. by the ISCIII (CPII18/00028). All Spanish funding is co-sponsored by the European Union FEDER program.

Published
2020

23. Pembrolizumab as Consolidation Strategy in Patients with Multiple Myeloma: Results of the GEM-Pembresid Clinical Trial

Author

Puig, N., Corchete Sánchez, Luis Antonio, Pérez-Morán, J. J., Dávila, J., Paíno, T., de la Rubia, J., Oriol, Albert, Martín-Sánchez, J., de Arriba, F., Bladé, J., Blanchard, M. J., González-Calle, V., Garcia-Sanz, R., Paiva, Bruno, Lahuerta, J. J., San-Miguel, J. F., Mateos, M. V., Ocio, E. M., Universitat Autònoma de Barcelona, and Universidad de Cantabria

Subjects
0301 basic medicine, Oncology, Melphalan, Cancer Research, medicine.medical_specialty, medicine.medical_treatment, Pembrolizumab, lcsh:RC254-282, Article, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Adverse effect, Multiple myeloma, Pneumonitis, business.industry, Late effect, Immunotherapy, medicine.disease, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Discontinuation, 030104 developmental biology, myeloma, 030220 oncology & carcinogenesis, pembrolizumab, immunotherapy, medicine.symptom, business, consolidation, medicine.drug
Abstract

PD1 expression in CD4+ and CD8+ T cells is increased after treatment in multiple myeloma patients with persistent disease. The GEM-Pembresid trial analyzed the efficacy and safety of pembrolizumab as consolidation in patients achieving at least very good partial response but with persistent measurable disease after first- or second-line treatment. Moreover, the characteristics of the immune system were investigated to identify potential biomarkers of response to pembrolizumab. One out of the 17 evaluable patients showed a decrease in the amount of M-protein, although a potential late effect of high-dose melphalan could not be ruled out. Fourteen adverse events were considered related to pembrolizumab, two of which (G3 diarrhea and G2 pneumonitis) prompted treatment discontinuation and all resolving without sequelae. Interestingly, pembrolizumab induced a decrease in the percentage of NK cells at cycle 3, due to the reduction of the circulating and adaptive subsets (0.615 vs. 0.43, p = 0.007, 1.12 vs. 0.86, p = 0.02). In the early progressors, a significantly lower expression of PD1 in CD8+ effector memory T cells (MFI 1327 vs. 926, p = 0.03) was observed. In conclusion, pembrolizumab used as consolidation monotherapy shows an acceptable toxicity profile but did not improve responses in this MM patient population. The trial was registered at clinicaltrials.gov with identifier NCT02636010 and with EUDRACT number 2015-003359-23.

Published
2020

24. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group

Author

de Larrea, Fernandez C, Kyle, R A, Durie, B GM, Ludwig, H, Usmani, S, Vesole, D H, Hajek, R, San Miguel, J F, Sezer, O, Sonneveld, P, Kumar, S K, Mahindra, A, Comenzo, R, Palumbo, A, Mazumber, A, Anderson, K C, Richardson, P G, Badros, A Z, Caers, J, Cavo, M, LeLeu, X, Dimopoulos, M A, Chim, C S, Schots, R, Noeul, A, Fantl, D, Mellqvist, U-H, Landgren, O, Chanan-Khan, A, Moreau, P, Fonseca, R, Merlini, G, Lahuerta, J J, Blade, J, Orlowski, R Z, and Shah, J J

Published
2013
Full Text
View/download PDF

27. Results of pre- and post-autologous stem cell transplantation with three induction regimens in multiple myeloma: superiority of VTD (bortezomib /thalidomide /dexamethasone) over TD and VBMCP/VBAD plus bortezomib (VBMCP/VBAD/V): 0271

Author

Rosiñol, L., Cibeira, M. T., Mateos, M. V., Gutierrez, N., Martínez, J., Oriol, A., Teruel, A. I., Hernández, D., García-Laraña, J., de la Rubia, J., Sureda, A., Besalduch, J., Palomera, L., González, Y., Etxebeste, M. A., Díaz-Mediavilla, J., Hernández, M. T., de Arriba, F., Alegre, A., Lahuerta, J. J., Miguel, San J., and Bladé, J.

Published
2011

28. Corrigendum: Second primary malignancies in multiple myeloma: an overview and IMWG consensus

Author

Musto, P, Anderson, K. C, Attal, M, Richardson, P. G, Badros, A, Hou, J, Comenzo, R, Du, J, Durie, B. G. M, San Miguel, J, Einsele, H, Chen, W. M, Garderet, L, Pietrantuono, G, Hillengass, J, Kyle, R. A, Moreau, P, Lahuerta, J. J, Landgren, O, Ludwig, H, Larocca, A, Mahindra, A, Cavo, M, Mazumder, A, McCarthy, P. L, Nouel, A, Rajkumar, S. V, Reiman, A, Riva, E, Sezer, O, Terpos, E, Turesson, I, Usmani, S, Weiss, B. M, Palumbo, A., Musto, P, Anderson, K. C, Attal, M, Richardson, P. G, Badros, A, Hou, J, Comenzo, R, Du, J, Durie, B. G. M, San Miguel, J, Einsele, H, Chen, W. M, Garderet, L, Pietrantuono, G, Hillengass, J, Kyle, R. A, Moreau, P, Lahuerta, J. J, Landgren, O, Ludwig, H, Larocca, A, Mahindra, A, Cavo, M, Mazumder, A, Mccarthy, P. L, Nouel, A, Rajkumar, S. V, Reiman, A, E, Riva, Sezer, O, Terpos, E, Turesson, I, Usmani, S, Weiss, B. M, and Palumbo, A.

Subjects
NA
Abstract

Erratum to: Annals of Oncology, Volume 28, Issue 2, 1 February 2017, Pages 228–245, https://doi.org/10.1093/annonc/mdw606

Published
2018

29. High-dose therapy/autologous stem cell transplantation increases complete remission rate in multiple myeloma irrespective of the induction regimen used: TD (Thalidomide/dexamethasone), VTD (bortezomib/thalidomide/dexamethasone) or VBMCP/VBAD plus bortezom: O162

Author

Rosiñol, L., Cibeira, M. T., Martínez, J., Mateos, M. V., Terol, M. J., de la Rubia, J., Palomera, L., de Arriba, F., Oriol, A., Alegre, A., Besalduch, J., de Paz, R., García-Laraña, J., Díaz-Mediavilla, J., Sureda, A., Lahuerta, J. J., San Miguel, J., and Bladé, J.

Published
2009

34. Effectiveness of Lenalidomide in Patients with Relapsed or Progressive Multiple Myeloma: A114

Author

Amor, A A, Casanova, M, Fuertes, M, Guzmán, J L, Bueno, B A, Giraldo, P, Cánovas, A, Ibáñez, A, Castillo, I, Blanes, M, Ríos, E, Rodríguez, J N, Palomera, L, Hernández, M T, Oriol, A, Sancho, E, Menchaca, C, Vercher, J, González, A P, Arilla, M J, Ramírez, G, Pérez, R, Asensio, A, de la Serna, J, Osorio, S, Aguilar, C, Ansó, V, Calvo, J M, López, L, López, A, Olalla, J I, Hernández, J M, Petit, J, Ríos, P, Villalón, L, García, I, García, A, Larregla, S, García-Escribano, F L, and Lahuerta, J J

Published
2009

38. Tandem autologous transplant versus reduced-intensity conditioned allogeneic transplant in chemosensitive patients with multiple myeloma not achieving complete remission or near-CR with a first autologous transplant. Final results from a PHETEMA study

Author

Rosiñol, L., Lahuerta, J. J., Sureda, A., de la Rubia, J., García-Laraña, J., Hernández-García, M., Hernández-Ruíz, B., Pérez-Simón, J. A., Bello, J. L., Carrera, D., Peñarrubia, M. J., Abella, E., León, A., Poderós, C., García-Ruíz, J. C., Besalduch, J., Martínez-Martínez, R., Fernández-Pérez, I., Ribas, P., San Miguel, J., and Bladé, J.

Published
2008

40. Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature

Author

Rodríguez-Otero, P., Mateos, M. V., Martínez-López, J., Hernández, M. T., Ocio, E. M., Rosiñol, L., Martínez, R., Teruel, A. I., Gutiérrez, N. C., Bargay, Joan, Bengoechea, Enrique, González, Y., Perez de Oteyza, Jaime, Gironella, Mercedes, Nuñez-Córdoba, J. M., Encinas, C., Martín, Jesús, Cabrera, Carlos, Palomera, L., De Arriba, Felipe, Cedena, María Teresa, Puig, N., Oriol, Albert, Paiva, Bruno, Bladé Creixenti, Juan, Lahuerta, J. J., San Miguel, J. F., Universitat Autònoma de Barcelona, Institut Català de la Salut, [Rodríguez-Otero P] Clínica Universidad de Navarra, Pamplona, Spain. [Mateos MV, Ocio EM] Complejo Asistencial Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca, Salamanca, Spain. [Martínez-López J] Hospital Universitario 12 de Octubre, Instituto de Investigación 12 de Octubre, Madrid, Spain. [Hernández MT] Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain. [Rosiñol L] Hospital Clinic I Provincial, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain. [Gironella M] Hospital Universitari Vall d'Hebron, Barcelona, Spain., and Vall d'Hebron Barcelona Hospital Campus

Subjects
Oncology, Male, Otros calificadores::Otros calificadores::/prevención & control [Otros calificadores], medicine.medical_specialty, MRD Negativity, humanos, Population, gammopatía monoclonal de relevancia indeterminada, mieloma múltiple, lcsh:RC254-282, Biological Factors::Biomarkers [CHEMICALS AND DRUGS], Transplant ineligible, Monoclonal Gammopathy of Undetermined Significance, Article, Persones grans, factores biológicos::biomarcadores [COMPUESTOS QUÍMICOS Y DROGAS], Other subheadings::Other subheadings::/prevention & control [Other subheadings], 03 medical and health sciences, 0302 clinical medicine, Text mining, Internal medicine, medicine, neoplasias::neoplasias por tipo histológico::neoplasias de células plasmáticas::mieloma múltiple [ENFERMEDADES], Humans, education, personas::Grupos de Edad::adulto::anciano [DENOMINACIONES DE GRUPOS], Multiple myeloma, Aged, anciano, education.field_of_study, business.industry, Mieloma múltiple - Prognosi, Neoplasms::Neoplasms by Histologic Type::Neoplasms, Plasma Cell::Multiple Myeloma [DISEASES], Hematology, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, medicine.disease, Predictive value, Disease control, Novel agents, Persons::Age Groups::Adult::Aged [NAMED GROUPS], 030220 oncology & carcinogenesis, Marcadors bioquímics, Female, business, Multiple Myeloma, 030215 immunology
Abstract

Disease control at 5 years would be a desirable endpoint for elderly multiple myeloma (MM) patients, but biomarkers predicting this are not defined. Therefore, to gain further insights in this endpoint, a population of 498 newly diagnosed transplant-ineligible patients enrolled in two Spanish trials (GEM2005MAS65 and GEM2010MAS65), has been analyzed. Among the 435 patients included in this post-hoc study, 18.6% remained alive and progression free after 5 years of treatment initiation. In these patients, overall survival (OS) rate at 10 years was 60.8% as compared with 11.8% for those progressing within the first 5 years. Hemoglobin (Hb) >= 12 g/dl (OR 2.74, p = 0.001) and MGUS-like profile (OR 4.18, p = 0.005) were the two baseline variables associated with long-term disease-free survival. Upon including depth of response (and MRD), Hb >= 12 g/dl (OR 2.27) and MGUS-like signature (OR 7.48) retained their predictive value along with MRD negativity (OR 5.18). This study shows that despite the use of novel agents, the probability of disease control at 5 years is still restricted to a small fraction (18.6%) of elderly MM patients. Since this endpoint is associated with higher rates of OS, this study provides important information about diagnostic and post-treatment biomarkers helpful in predicting the likelihood of disease control at 5 years., This study was supported by the Centro de Investigacion Biomedica en Red-Area de Oncologia-del Instituto de Salud Carlos III (CIBERONC; CB16/12/00369 and CB16/12/00377), Instituto de Salud Carlos III/Subdireccion General de Investigacion Sanitaria (FIS no. PS09/01897/01370, PI12/01761, PI12/02311, PI13/01469, PI14/01867, G03/136, CD13/00340), Asociacion Espanola Contra el Cancer (GCB120981SAN) and the European Research Council (ERC) 2015 Starting Grant (MYELOMANEXT).

Published
2019

41. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkinʼs lymphoma autografted after a first relapse

Author

Sureda, A., Constans, M., Iriondo, A., Arranz, R., Caballero, M. D., Vidal, M. J., Petit, J., López, A., Lahuerta, J. J., Carreras, E., García-Conde, J., García-Laraña, J., Cabrera, R., Jarque, I., Carrera, D., García-Ruiz, J. C., Pascual, M. J., Rifón, J., Moraleda, J. M., Pérez-Equiza, K., Albó, C., Díaz-Mediavilla, J., Torres, A., Torres, P., Besalduch, J., Marín, J., Mateos, M. V., Fernández-Rañada, J. M., Sierra, J., and Conde, E.

Published
2005

42. Autologous stem-cell transplantation in diffuse large B-cell non-Hodgkinʼs lymphoma not achieving complete response after induction chemotherapy: the GEL/TAMO experience

Author

Rodriguez, J., Caballero, M. D., Gutierrez, A., Solano, C., Arranz, R., Lahuerta, J. J., Sierra, J., Gandarillas, M., Perez-Simon, J. A., Zuazu, J., Lopez-Guillermo, A., Sureda, A., Carreras, E., Garcia-Laraña, J., Marin, J., Garcia, J. C., Fernandez de Sevilla, A., Rifon, J., Varela, R., Jarque, I., Albo, C., Leon, A., Miguel, J. San, and Conde, E.

Published
2004

46. High-dose therapy in diffuse large cell lymphoma: results and prognostic factors in 452 patients from the GEL-TAMO Spanish Cooperative Group

Author

Caballero, M. D., Pérez-Simón, J. A., Iriondo, A., Lahuerta, J. J., Sierra, J., Marín, J., Gandarillas, M., Arranz, R., Zuazu, J., Rubio, V., de Sevilla, A. Fernández, Carreras, E., García-Conde, J., García-Laraña, J., Grande, C., Sureda, A., Vidal, M. J., Rifón, J., Pérez-Equiza, C., Varela, R., Moraleda, J. M., Ruíz, J. C. García, Albó, C., Cabrera, R., Miguel, J. F. San, and Conde, E.

Published
2003

47. PS1348 DETAILED PHENOTYPIC, MOLECULAR AND FUNCTIONAL PROFILING OF MYELOID DERIVED SUPPRESSOR CELLS (MDSCS) IN THE TUMOR IMMUNE MICRO-ENVIRONMENT (TIME) OF MULTIPLE MYELOMA (MM)

Author

Pérez, C., primary, Botta, C., additional, Zabaleta, A., additional, Puig, N., additional, Cedena, M.T., additional, Merino, J., additional, Alignani, D., additional, Garate, S., additional, Goicoechea, I., additional, Lara-Astiaso, D., additional, Sarvide, S., additional, Martínez-López, J., additional, Oriol, A., additional, Ríos, R., additional, Rosiñol, L., additional, Mateos, M.-V., additional, Lahuerta, J.-J., additional, Bladé, J., additional, San-Miguel, J.F., additional, and Paiva, B., additional

Published
2019
Full Text
View/download PDF

48. S871 CURATIVE STRATEGY (GEM-CESAR) FOR HIGH-RISK SMOLDERING MYELOMA: CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE (KRD) AS INDUCTION FOLLOWED BY HDT-ASCT, CONSOLIDATION WITH KRD AND MAINTENANCE WITH RD

Author

Mateos, M.-V., primary, Martínez-López, J., additional, Rodríguez-Otero, P., additional, González de la Calle, V., additional, González, M.-S., additional, Oriol, A., additional, Gutiérrez, N.-C., additional, Paiva, B., additional, Rios, R., additional, Rosiñol, L., additional, Alvarez, M.-A., additional, Calasanz, M.-J., additional, Bargay, J., additional, González, A.-P., additional, Alegre, A., additional, Escalante, F., additional, Martínez, R., additional, Puig, N., additional, de la Rubia, J., additional, Teruel, A.-I., additional, Cedena, M.-T., additional, de Arriba, F., additional, Palomera, L., additional, Hernández, M.-T., additional, López, J., additional, Martín, J., additional, García-Mateo, A., additional, Ocio, E., additional, Bladé, J., additional, Lahuerta, J.-J., additional, and San Miguel, J., additional

Published
2019
Full Text
View/download PDF

49. S121 SINGLE-CELL CHARACTERIZATION OF THE MULTIPLE MYELOMA (MM) IMMUNE MICROENVIRONMENT IDENTIFIES CD27- T CELLS AS POTENTIAL SOURCE OF TUMOR-REACTIVE LYMPHOCYTES

Author

Botta, C., primary, Perez, C., additional, Puig, N., additional, Cedena, M.T., additional, Cordon, L., additional, Zabaleta, A., additional, Burgos, L., additional, Maia, C., additional, Goicoechea, I., additional, Rodriguez, S., additional, Rodriguez, I., additional, Sarvide, S., additional, Alignani, D., additional, Vilas-Zornoza, A., additional, Lorenzo-Vivas, E., additional, Rosiñol, L., additional, Oriol, A., additional, Blanchard, M.-J., additional, Rios, R., additional, Sureda, A., additional, Martinez, R., additional, Martin, J., additional, Bargay, J., additional, de la Rubia, J., additional, Rossi, M., additional, Tagliaferri, P., additional, Tassone, P., additional, Merino, J., additional, Prosper, F., additional, Orfao, A., additional, Mateos, M.-V., additional, Lahuerta, J.-J., additional, Bladé, J., additional, San Miguel, J., additional, and Paiva, B., additional

Published
2019
Full Text
View/download PDF

50. Erratum: A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control

Author

Paiva, B, Vídriales, M-B, Rosiñol, L, Martínez-López, J, Mateos, M-V, Ocio, E M, Montalbán, M-Á, Cordón, L, Gutiérrez, N C, Corchete, L, Oriol, A, Terol, M-J, Echeveste, M-A, De Paz, R, De Arriba, F, Palomera, L, de la Rubia, J, Díaz-Mediavilla, J, Granell, M, Gorosquieta, A, Alegre, A, Orfao, A, Lahuerta, J-J, Bladé, J, and San Miguel, J F

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results